H. Lundbeck, Interim report for the nine months ended 30 September 2003

Today the Supervisory Board of H. Lundbeck A/S approved the company's interim report for the first nine months of 2003 a period influenced by intensified generic competition and the launch of Lundbeck's two new drugs Cipralex® and Ebixa®.